0000000000790843

AUTHOR

Emmanuelle Hammad

showing 3 related works from this author

Choosing the Right Antifungal Agent in ICU Patients

2019

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the phar…

AzolesAntifungal AgentsReviewKidney Function TestsInvasive aspergillosiEchinocandins0302 clinical medicineLiver Function Tests[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineDrug InteractionsPharmacology (medical)030212 general & internal medicineComputingMilieux_MISCELLANEOUSmedia_common[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesIncidenceIncidence (epidemiology)CandidiasisGeneral MedicineSerum concentrationIntensive care patients3. Good healthIntensive Care UnitsPractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCandidiasiNarrative reviewDrug MonitoringInvasive fungi infectionAntifungalDrugmedicine.medical_specialtyIcu patientsmedicine.drug_classmedia_common.quotation_subjectPharmacokineticPolyenesImmunocompromised Host03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careHumansPharmacokinetics[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care medicineIntensive care patient030306 microbiologybusiness.industry[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyInvasive aspergillosisLiver functionbusinessPractical guidelinesInvasive Fungal InfectionsAdvances in Therapy
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct

Choosing the Right Antifungal Agent in ICU Patients

2019

Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparen…

researchProduct